We succeeded in xenografting an adenoid cystic carcinoma of the parotid gland into athymic mice. It could be maintained by serial subcutaneous implantation~for more than 37 passages.For further characterization of this adenoid cystic carcinoma it was tested for the expression of different antigens by use of monoclonal antibodies in an indirect immunoperoxidase assay. Positive binding was observed with the monoclonal antibody OKIa (Ortho,Raritan N.J.),detecting human HLA-DR framework. There was no cross reactivity with mouse tissues,and up to 100% of tumor cells stainedpositive.Monoclonal antibodies reacting with different epithel associated antigens were kind gifts of D~s.Hilgers and Hilkens,Nederland Cancer Inst. Amsterdam,and Dr. Taylor-Papadimitriou,ICRF,London. Antibody HMFGI reacted with app.10% of human tumor cells,but showed also cross reactivity with murine thyreoid gland,pancreas,lung and parotid gland.Antibody HMFG2 bound to only 5% of human tumor cells,but showed only slight cross reactivity with murine thyreoid gland.Antibody d8 even bound to 20% of human tumor cells,but showed considerable cross reactivity with the murine tissues mentioned above.Antibody d11 exhibited no binding to human tumor tissue,but reacted also with the above mentioned murine tissues.Our results show, that the expression of HLA-DR framework is maintained also after xenografting. One may assume, that this malignancy arose from the acinar cells of the parotid gland known to express HLA-DRphys~ologically. The positive reaction of HMFGI,hMFG2 and d8 with human malignant tissue and normal murine glandular tissues provides evidence,that these antigens can be expressed in different species. 41%. lhe distribution in sex (2B males and 17 famles ) as well as the localisation ( 66 % minor and 33% major salivary glands ) differed from the literature. lhe advantages offered by omlx~rized imaging in form of CT and ~, could be used for a better evaluation of ccmplex anatonical sites, especially in the nasal cavities and the paranasal sinuses during recto years, lheir diagnostic value has to be f~re elucidated in other and following studies. In cur hospital therapeffcic preference was a non radical i~ surgery ( differing from Conley ) in ccmbination with subsequerfc radio -therapy.
During a follow -up period of up to 15 years, only 17 patients died from tumor distress. 8 patients survived with I~) after surgical procedure only for up to 13 years. lhus both groups show better results conceming martality, than could have been expected from several literature data. These early results in the treatment of adenoid -cystic -carcinoma favour ~ned concept. A critical review is p~ with special regards to diagnostic pitfalls and therapeutic pathways. 
ON PROGNOSTIC VALUE OF HISTOLOGY AND LOCALI-ZATION IN CARCINOMAS OF MAJOR AND MINOR SALI-VARY GLANDS I. Koblin
Histological type of salivary gland carcinoma by most authors is regarded as a conclusive prognostic factor. But there is also evidence that the site of origin has the same or even more influence on prognosis.
In a prospective study initiated and compiled by the D~SAK since 1977, about 200 patients with salivary gland carcinomas which had not been treated previously were followed up from I to 8 years. The preliminary results are: On the one hand squamous cell carcinoma, acinic cell and mucoepidermoid carcinema arising in the parotid gland show a lower surviving rate than adenoid cystic carcinoma or carcinoma in pleomorphic adenoma; on the other hand it can be observed likewise that salivary gland carcinomas arising in the oral cavity generally have a better prognosis than those of the parotid gland, the worst those of the submandibular gland.
Altogether in the individual case the prognosis depends on two factors:the histological type of salivary gland carcinoma as well as the site of origin. Continuation of the present study has the purpose to determine these fac tors more precisely. The chemotherapy consisted of a combination of vincristin (1.4mg/m 2 i.v. injection on day I and 8), methotrexate (120mg/m 2 i.v. infusion over 20 hours with leucoverin rescue on day 2, 5, 9 and 12) and bleomycin (30mg i.v. infusion over I hour on day 3, 6, 10 and 13). So far, 126 patients entered the study, 48 patients for group A, 38 for group B and 40 patients for group C. The average age in group A was 57.9 years, in group B 55.2 and in group C 58.8 years. Group A compromised 81,3% male and 18,7% female patients, group B 76,3% and 23,7% and group C 90% and 10% respectively. The lymphnode stage in group A was 31.3% N O , 35.4% NI, 27.1% Np and 6.3% NR; in group B 34.2% N n, 47.4% N~, 15.8% N~ and 2.6% N~ and in group C 52.5% N n, 27.5% N~, 17.5% N~ and 2.5% N~. Due to toxicity, the ~he-mothera~y war interrupted in 8 patients in group A and in 5 patients in group B. Break off of the chemotherapy was necessary in 5 patients in group A and in 4 patients in group B. Based upon the data accumulated thus far, it is concluded that there is no statistically significant difference between the three treatment groups after 3 years.
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